Pioneering allergy research

Under­standing allergy

ALK has an unrivalled understanding of allergens and how they affect the human body, as well as the link between allergy and respiratory diseases such as asthma.



  • Post date
    ACARIZAX® approved in Europe for use in adolescent patients with house dust mite-induced allergic rhinitis
  • Post date
    ALK’s partner, Torii, submits paediatric registration application for the house dust mite SLIT-tablet in Japan
  • Post date
    Grant of share options and performance shares to members of the Board of Management and key employees
  • Post date
    Annual General Meeting in ALK-Abelló A/S held on 15 March 2017
  • Post date
    ALK appoints SVP of R&D for North America and International Markets
  • Post date
    ALK announces FDA approval for its house dust mite sublingual allergy immunotherapy tablet (ACARIZAX® in Europe)
  • Post date
    ALK’s ACARIZAX® data results in significant change to the GINA asthma management strategy: Sublingual allergy immunotherapy (SLIT) recommended as a treatment option in patients with house dust mite allergic asthma
  • Post date
    ALK submits registration application for ragweed SLIT-tablet in Europe
  • Post date
    Annual General Meeting in ALK-Abelló A/S on 15 March 2017
Prevention of asthma symptoms
ALK is leading the industry’s research into the role respiratory allergies play in asthma. As part of this research, we conducted the world’s largest allergy immunotherapy trial ever carried out in children to investigate the effect of a new treatment on the risk of developing asthma.
The link between allergic rhinitis and allergic asthma
Respiratory allergens, such as house dust mites, can cause the airways to inflame. In time, this can lead to asthma, or the worsening of symptoms in people who are already asthmatic. A new treatment option can treat both house dust mite allergic rhinitis and allergic asthma.

ALK in brief

ALK at a glance
ALK is a research-driven, global pharmaceutical company focusing on allergy prevention, diagnosis and treatment. We are the foremost innovators in allergy immunotherapy – a unique treatment which reduces allergic symptoms and treats the cause of the allergy.
Global presence
ALK employs around 2,000 employees worldwide and has affiliates, production facilities and distributors around the globe. Today, around 1.5 million people worldwide use our products.
ALK's pipeline
Our development programme covers the four most important outdoor allergens in Europe, the USA and Japan (grass, birch and related trees, ragweed and Japanese cedar) and the most important indoor allergen in the world (house dust mites).
ALK's history
ALK has been at the forefront of allergy treatment for almost a century. Our story can be traced back to a small laboratory in Copenhagen, Denmark, in 1923.